

## DAFTAR PUSTAKA

1. Beig J, Orr D, et al. Hepatitis C Virus Eradication with New Interferon-Free Treatment Improves Metabolic Profile in Hepatitis C Virus-Related Liver Transplant Recipients. *Liver Transplant*. 2018;24:1031–9.
2. Manns MP, Buti M, et al. Hepatitis C virus infection. *Nat Rev Dis Prim*. 2017;3:1–19.
3. Gani RA. Hepatitis C. In: Setiati S, Alwi I, Syam AF, editors. *Buku Ajar Ilmu Penyakit Dalam*. VI. Jakarta: Interna Publishing; 2014. p. 1972–7.
4. Waworuntu W, Dwisangka S, et al. Virologi Dan Perjalanan Penyakit Hepatitis C. In: *Panduan Singkat Tatalaksana Hepatitis C*. 1st ed. Jakarta: Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan RI; 2017. p. 3–17.
5. Wu GHM, Yang WW, et al. The epidemiological profile of chronic hepatitis C with advanced hepatic fibrosis regarding virus genotype in Taiwan: A nationwide study. *J Formos Med Assoc*. 2021;120(7):1444–51.
6. Hasan I, Gani RA, et al. *Konsensus Nasional Penatalaksanaan Hepatitis C di Indonesia*. 1st ed. Jakarta: Perhimpunan Peneliti Hati Indonesia; 2017. 1–49 p.
7. Basyte-Bacevice V, Kupcinskas J. Evolution and Revolution of Hepatitis C Management: From Non-A, Non-B Hepatitis Toward Global Elimination. *Dig Dis*. 2020;38(2):137–42.
8. Soliman EMK, Morsy HAA, et al. Predictor factors of sustained virological response in patients with chronic hepatitis C treated with current direct-

- acting antiviral drugs. *Trop J Pharm Res.* 2020;19(9):2015–20.
9. Tran K, Kuwajima VK, et al. Impact of Obesity on Treatment of Chronic Hepatitis C in Interferon-Free Direct-Acting Antiviral Era. In: *AASLD The Liver Meeting 2018.* San Francisco; 2018. p. 681.
  10. Aziz H, Aziz M, et al. Analysis of Host and Viral-Related Factors Associated to Direct Acting Antiviral Response in Hepatitis C Virus Patients. *Viral Immunol.* 2018 Apr;31(3):256–63.
  11. Li DK, Chung RT. Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus. In: *Methods in Molecular Biology.* New York: Humana Press; 2019. p. 3–32.
  12. Rheem J, Sundaram V, et al. Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection. *Gastroenterol Hepatol (N Y).* 2015 May;11(5):294–346.
  13. Reid M, Price JC, et al. Hepatitis C Virus Infection in the Older Patient. *Infect Dis Clin North Am.* 2017;31(4):827–38.
  14. Sherigar JM, Gayam V, et al. Clinical efficacy and tolerability of direct-acting antivirals in elderly patients with chronic hepatitis C. *Eur J Gastroenterol Hepatol.* 2017;29(7):767–76.
  15. Kamel S, Elessawy H, et al. Effectiveness of Direct-Acting Antivirals in Treatment of Elderly Egyptian Chronic Hepatitis C Patients. *Gastroenterol Insights.* 2021;12(3):336–46.
  16. Baden R, Rockstroh JK, et al. Natural History and Management of Hepatitis C: Does Sex Play a Role? *J Infect Dis.* 2014;209(Suppl 3):S81-5.

17. Bakr I, Rekecewicz C, et al. Higher clearance of hepatitis C virus infection in females compared with males. *Gut*. 2006 Aug;55(8):1183–7.
18. Yan Z, Wang Y. Viral and host factors associated with outcomes of hepatitis C virus infection (Review). *Mol Med Rep*. 2017;15(5):2909–24.
19. Cavalcante LN, Lyra ACAC. Predictive factors associated with hepatitis C antiviral therapy response. *World J Hepatol*. 2015;7(12):1617–31.
20. Yu J-W, Sun L-J, et al. Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment. *Int J Infect Dis*. 2011 Nov 1;15(11):e740-6.
21. Floreani A, Cazzagon N, et al. Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response. *Eur J Gastroenterol Hepatol*. 2011;23(11):997–1003.
22. Kanwal F, Kramer JR, et al. Race and Gender Differences in the Use of Direct Acting Antiviral Agents for Hepatitis C Virus. *Clin Infect Dis*. 2016;63(3):291–9.
23. Yuniastuti E, Hariyanto R, et al. Hepatitis C continuum of care: Experience of integrative hepatitis C treatment within a human immunodeficiency virus clinic in Indonesia. *PLoS One*. 2021;16(8):1–10.
24. Alsö A, Rembeck K, et al. Impact of Obesity on the Bioavailability of Peginterferon- $\alpha$ 2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3. *PLoS One*. 2012 May 24;7(5):e37521.
25. Hsu SJ, Chiu MC, et al. Real-world effectiveness and safety of

- glecaprevir/pibrentasvir in Asian patients with chronic hepatitis C. *J Formos Med Assoc.* 2019 Aug;118(8):1187–92.
26. Irshad M, Dhar I. Hepatitis C virus core protein: An update on its molecular biology, cellular functions and clinical implications. *Med Princ Pract.* 2006 Oct;15(6):405–16.
  27. Holzmann I, Tovo C V., et al. Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil. *Brazilian J Infect Dis.* 2018 Jul;22(4):317–22.
  28. Honda T, Ishigami M, et al. Hepatitis C Treatment in Elderly Patients. In: Smolic M, editor. *Update on Hepatitis C.* InTech; 2017. p. 65–73.
  29. Nelson DR, Cooper JN, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. *Hepatology.* 2015;61(4):1127–35.
  30. Foster GR, Asselah T, et al. Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. *PLoS One.* 2019 Jan;14(1):1–13.
  31. Machado SM, Vigani AG, et al. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfecting individuals: A multicenter study. *Medicine (Baltimore).* 2020;99(30):1–8.
  32. Villa E, Karampatou A, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. *Gastroenterology.* 2011 Mar 1;140(3):818–29.
  33. Luz Narciso-Schiavon J, de Lucca Schiavon L, et al. Gender influence on

- treatment of chronic hepatitis C genotype 1. *Rev Soc Bras Med Trop.* 2010;43(3):217–23.
34. Pham TT, Keast SL, et al. Sustained virologic response and costs associated with direct-acting antivirals for chronic hepatitis C infection in Oklahoma Medicaid. *J Manag Care Spec Pharm.* 2018;24(7):664–76.
  35. Bressler B, Wang K, et al. Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN  $\alpha$ -2a (40KD) (PEGASYS®). *Br J Clin Pharmacol.* 2009;67(3):280.
  36. Charlton MR, Pockros PJ, et al. Impact of obesity on treatment of chronic hepatitis C. *Hepatology.* 2006 Jun;43(6):1177–86.
  37. Gupta V, Kumar A, et al. Most Patients of Hepatitis C Virus Infection in India Present Late for Interferon-Based Antiviral Treatment: An Epidemiological Study of 777 Patients from a North Indian Tertiary Care Center. *J Clin Exp Hepatol.* 2015;5(2):134–41.
  38. Wang Y, Rao H, et al. Detection of residual HCV-RNA in patients who have achieved sustained virological response is associated with persistent histological abnormality. *EBioMedicine.* 2019;46(168):227–35.
  39. Pott-Junior H, Bricks G, et al. Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial. *Clin Microbiol Infect.* 2019 Mar 1;25(3):365–71.
  40. Charatchoenwittaya P, Wongpaitoon V, et al. Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic

- hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. *BMC Gastroenterol.* 2020 Mar 5;20(1):1–15.
41. Zoratti MJ, Siddiqua A, et al. Pangenotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection: A systematic literature review and meta-analysis. *EClinicalMedicine* [Internet]. 2020;18:100237. Available from: <https://doi.org/10.1016/j.eclinm.2019.12.007>
  42. Elbaz T, Abdo M, et al. Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. *J Med Virol.* 2019;91(2):272–7.
  43. Pariente A, Arpurt JP, et al. Effects of age on treatment of chronic hepatitis C with direct acting antivirals. *Ann Hepatol.* 2019;18(1):193–202.
  44. Xia H, Zhang Y, et al. Direct-acting antiviral treatments display excellent outcomes even in older HCV-infected patients at increased risk of fibrosis. *Ann Transl Med.* 2021;9(10):1–14.
  45. Margusino-Framiñán L, Cid-Silva P, et al. Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis c virus infected patients. Results in real clinical practice. *Rev Esp Quimioter.* 2019;32(2):137–44.
  46. Ahmed OA, Safwat E, et al. Sofosbuvir plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients: An experiment the size of egyptian village. *Int J Hepatol.* 2018;2018.
  47. Yang Y, Wu F-P, et al. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1,

- 2 and 3 in northwest China. *World J Gastroenterol.* 2019;25(44):6551–60.
48. Belci P, Collo A, et al. Can gender predict virological response to standard antiviral therapy for chronic hepatitis C? A retrospective study. *Hepatoma Res.* 2016;2(5):122.
49. Allam AS, Anwar AG, et al. Impact Of Obesity On Sustained Virologic Response To Sofosbuvir Based Regimens In The Egyptian Chronic Hepatitis C Patients. *J Egypt Soc Parasitol.* 2019;49(3):699–706.
50. Gupta S, Rout G, et al. Efficacy of Generic Oral Directly Acting Agents in Patients with Hepatitis C Virus Infection. *J Viral Hepat.* 2018;25(7):771–8.
51. Gayam V, Mandal AK, et al. Sofosbuvir Based Regimens in the Treatment of Chronic Hepatitis C with Compensated Liver Cirrhosis in Community Care Setting. *Int J Hepatol.* 2018;2018:1–9.